Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Tuesday, May 12, 2009

Antimicrobial Protein Produced by Vaginal Lactobacillus acidophilus that inhibits Gardnerella vaginalis

Alla A. Aroutcheva, Jose A. Simoes, and Sebastian Faro
Department of Obstetrics and Gynecology, Rush-Presbyterian-St. Luke's Medical Center, 1653W. Congress Pkwy, 720 Pav., Chicago, IL, 60612, USA,
Infect Dis Obstet Gynecol 2001;9:33–39

Objective: The objective of this study was to develop a simple method for recovery and purification of the antimicrobial protein produced by endogenous vaginal L. acidophilus. Obtaining a pure bacteriocin will permit investigations leading to a better understanding of the interaction between the endogenous bacteria of the vagina..

All nine isolates of Gardnerella were inhibited by the bacteriocin isolated from L. acidophilus 160.
Methods: L. acidophilus 160 was grown on two media. The first was MRS broth for 18 hours; the cells were harvested, washed, and placed into a chemically defined medium. The second medium resembled vaginal fluid minus protein. Bacteriocin was precipitated from both media using ammonium sulfate. The growth-inhibiting activity of bacteriocin was determined by a bioassay using nine different isolates of Gardnerella vaginalis.

Results: MRS broth is not a suitable medium for extracting bacteriocin, because it binds with Tween 80. Bacteriocin was isolated, without contaminating constituents, from chemically defined medium and identified as a single band by electrophoresis. Bacteriocin has a molecular weight of 3.8 kDa. All nine isolates of Gardnerella were inhibited by the bacteriocin isolated from L. acidophilus 160.

Lactobacilli, through the antagonistic interaction
with pathogenic bacteria, maintain the vaginal ecosystem in a healthy state.
Conclusions: Bacteriocin produced by L. acidophilus 160 was isolated from the chemically defined medium (starvation medium) in a partially pure form. L. acidophilus 160 bacteriocin inhibited growth of all nine isolates of Gardnerella vaginalis

Lactobacilli, through the antagonistic interaction with pathogenic bacteria, maintain the vaginal ecosystem in a healthy state. Regulatory processes are carried out by species of Lactobacillus that produce antibacterial compounds, such as lactic and other organic acids, H2O2, and bacteriocins. Bacteriocins are biologically active, lowmolecular-weight proteins or peptides that inhibit the growth of a variety of bacteria.

The bacteriocin activity includes other species of lactobacilli, as well as a variety of Gram-positive and Gram-negative aerobic, facultative, and obligate anaerobic bacteria. It is significant that one species of Lactobacillus will produce a bacteriocin that inhibits the growth of other lactobacilli. This may be one mechanism that allows Lactobacillus to dominate the ecosystem by suppressing not only other bacteria but also other lactobacilli. This in turn reduces competition within an ecosystem.


Full text:

Related Posts:

Part 2 of interview with Cass Nelson-Dooley of Metametrix [keyword: lactobacillus]

Probiotics - Lactobacillus acidophilus


Post a Comment